In line with the observation that gpNMB expression is induced by the inhibition of MAPK pathway [71], combination of glembatumumab vedotin with MAPK pathway inhibitors demonstrated a synergistic therapeutic effect in a melanoma mouse model [71]. Here, GPNMB is linked to melanoma.